XFOR vs. MGTX, ARCT, KOD, GHRS, ATXS, TERN, CRMD, TKNO, ANAB, and ABVX
Should you be buying X4 Pharmaceuticals stock or one of its competitors? The main competitors of X4 Pharmaceuticals include MeiraGTx (MGTX), Arcturus Therapeutics (ARCT), Kodiak Sciences (KOD), GH Research (GHRS), Astria Therapeutics (ATXS), Terns Pharmaceuticals (TERN), CorMedix (CRMD), Alpha Teknova (TKNO), AnaptysBio (ANAB), and ABIVAX Société Anonyme (ABVX). These companies are all part of the "pharmaceutical products" industry.
X4 Pharmaceuticals vs.
MeiraGTx (NASDAQ:MGTX) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, community ranking, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.
X4 Pharmaceuticals has a net margin of 0.00% compared to MeiraGTx's net margin of -633.05%. MeiraGTx's return on equity of -146.38% beat X4 Pharmaceuticals' return on equity.
In the previous week, X4 Pharmaceuticals had 5 more articles in the media than MeiraGTx. MarketBeat recorded 11 mentions for X4 Pharmaceuticals and 6 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 0.62 beat X4 Pharmaceuticals' score of 0.24 indicating that MeiraGTx is being referred to more favorably in the media.
MeiraGTx presently has a consensus target price of $23.50, indicating a potential upside of 307.28%. X4 Pharmaceuticals has a consensus target price of $3.50, indicating a potential upside of 667.88%. Given X4 Pharmaceuticals' higher possible upside, analysts plainly believe X4 Pharmaceuticals is more favorable than MeiraGTx.
MeiraGTx has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500. Comparatively, X4 Pharmaceuticals has a beta of 0.14, suggesting that its share price is 86% less volatile than the S&P 500.
MeiraGTx received 115 more outperform votes than X4 Pharmaceuticals when rated by MarketBeat users. Likewise, 71.54% of users gave MeiraGTx an outperform vote while only 67.26% of users gave X4 Pharmaceuticals an outperform vote.
MeiraGTx has higher revenue and earnings than X4 Pharmaceuticals. X4 Pharmaceuticals is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.
67.5% of MeiraGTx shares are held by institutional investors. Comparatively, 72.0% of X4 Pharmaceuticals shares are held by institutional investors. 8.4% of MeiraGTx shares are held by company insiders. Comparatively, 1.6% of X4 Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
MeiraGTx beats X4 Pharmaceuticals on 10 of the 17 factors compared between the two stocks.
Get X4 Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for XFOR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
X4 Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:XFOR) was last updated on 1/14/2025 by MarketBeat.com Staff
